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Effect of Inhibitors of Arochidonic Acid Metabolism on
Corneal Neovascularization in the Rat
William L. Haynes, Alan D. Proia, and Gordon K. Klinrworrh
We used computerized image analysis to evaluate quantitatively the ability of topically applied cortico-
steroids (dexamethasone sodium phosphate, prednisolone acetate), cyclooxygenase inhibitors (flurbi-
profen, indomethacin, ketorolac), lipoxygenase inhibitors (REV 5901, esculetin, quercetin), and dual
cyclooxygenase/lipoxygenase inhibitors (BW 755C, BW A540C) to reduce corneal neovascularization
in the rat induced by silver/potassium nitrate cauterization. Significant decreases in the neovascular
response were found with corticosteroids and cyclooxygenase inhibitors. A complete dose-response
curve was performed for a representative compound from each class. Dexamethasone was found to be
superior to flurbiprofen in its ability to reduce neovascularization in this model, while no significant
inhibition was noted with either REV 5901 or BW 755C, even at high doses. We conclude that the
corneal angiogenic response in this model can be reduced by inhibition of cyclooxygenase as well as by
other mechanisms that are steroid-dependent but are, as yet, poorly defined. Invest Ophthalmol Vis
Sci 30:1588-1593,1989
Arachidonic acid (AA), a 20-carbon polyunsatu-
rated fatty acid, is metabolized to a variety of biologi-
cally active eicosanoids (Fig. 1). Prostaglandins, pros-
tacyclin and thromboxane are products of the cy-
clooxygenase pathway.1 The lipoxygenase pathways
convert AA to hydroxyeicosatetraenoic acids
(HETEs), leukotrienes and lipoxins, all of which can
stimulate chemotaxis of leukocytes.1"4 Recently, a
third pathway for AA metabolism dependent on cy-
tochrome P450 monooxygenases has been described.
The products of this pathway include vasodilatory
epoxyeicosatrienoic acids (EETs)5 and 12(R)-HETE,6
a chemotactic factor for neutrophils.7
Several lines of evidence support a role for arachi-
donic acid metabolites in the corneal neovascular re-
sponse: (1) prostaglandin E2 levels are increased in
the cornea following injury8; (2) some cells such as
activated macrophages9 and tumor cells,10 which
cause neovascularization when placed in the cornea,
generate eicosanoids; (3) Ben Ezra" and others12"14
have demonstrated that E series prostaglandins are
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potent stimulators of the neovascular response; and
(4) corticosteroids and nonsteroidal inhibitors of ara-
chidonic acid metabolism inhibit corneal neovascu-
larization in some models.15"21
A variety of compounds inhibit specific steps in the
metabolism of arachidonic acid (Fig. I).222"25 In an
attempt to implicate the pathways of AA metabolism
that are involved in corneal neovascularization, we
have used computerized image analysis to evaluate
quantitatively the ability of representative topically
applied corticosteroids, cyclooxygenase inhibitors, li-
poxygenase inhibitors and dual inhibitors of cycloox-
ygenase and lipoxygenases to reduce the neovascular
response to silver/potassium nitrate cautery in
the rat.
Materials and Methods
Animals
Male rats weighing 200-224 g were obtained from
Harlan Sprague Dawley Inc. (Indianapolis, IN). Food
(Rodent Laboratory Chow, Ralston Purina Co., St.
Louis, MO) and water were given ad libitum to all
animals throughout each experiment. For all experi-
ments, groups of eight rats were treated with drug or
drug vehicle. Rats were cared for and treated in ac-
cordance with the ARVO Resolution on the Use of
Animals in Research.
Drug Preparations
Dexamethasone sodium phosphate (Merck, Sharp,
and Dohme Research Laboratories, West Point, PA),
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prednisolone 21-acetate, quercetin, esculetin, pheni-
done (Sigma Chemical Co., St. Louis, MO), BW
755C, BW A540C (Burroughs Wellcome Co., Re-
search Triangle Park, NC), and REV 5901 (Barnes-
Hind Pharmaceuticals, Sunnyvale, CA) were pre-
pared in a Tween 20 buffer solution consisting of 10%
(by volume) Tween 20 (J. T. Baker Co., Phillipsburg,
NJ) dissolved in 0.9% saline with 5% (by volume) 0.2
M tris(hydroxymethyl)aminomethane (tris buffer),
pH 7.4. The vehicle containing Tween 20 was chosen
to enhance the penetration of the drugs into the cor-
nea.26 Indomethacin (Sigma) and flurbiprofen (The
Upjohn Co., Kalamazoo, MI) were prepared in the
same Tween 20-containing buffer solution with equi-
molar sodium carbonate added to aid in solubiliza-
tion. Prednisolone acetate (1.0%), quercetin (1.0%),
esculetin (1.0%), BW 755C (2.5% and 5.0%) and REV
5901 (1.0%, 2.5%, and 5.0%) were suspensions. All
other drug preparations were solutions. Each prepa-
ration had a pH of approximately 6.5-7.5. A control
group of animals treated only with the Tween 20
buffer solution was used for each experiment with the
above compounds.
Ketorolac tromethamine 0.5% ophthalmic solu-
tion and the corresponding drug vehicle were from
Syntex, Inc. (Palo Alto, CA).
Experimental Procedures
Both corneas of each rat were cauterized by press-
ing applicator sticks coated with 75% silver nitrate/
25% potassium nitrate (Graham-Field Surgical Co.,
Inc., New Hyde Park, NY) to the surface of the cor-
nea eccentrically at a point approximately 2.5 mm
from the corneoscleral limbus for 5 sec (timed using a
stopwatch) while the animal was deeply anesthetized
with ether.27 To increase the reproducibility of the
injuries, one of us cauterized all animals. Following
cauterization, the rats were randomized to eliminate
potential bias in the degree of injury within the dif-
ferent groups. Three 10 /A drops of each drug were
applied topically to each cauterized cornea four times
per day (8:00 AM, noon, 4:00 PM, 8:00 PM) for 4
days. Drops were given a few seconds apart and ani-
mals were allowed to blink between drops. The first
treatment with each medication was approximately
30 min after cauterization. This treatment regimen
was chosen for a variety of reasons, including similar-
ity to clinical procedure and similarity to previously
published studies. Three drops were given per eye
because the use of multiple drops appeared to en-
hance drug efficacy in preliminary experiments.
Dose-response curves were performed using a rep-
resentative compound from each class to determine
the effect of varying concentration on the ability to
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Fig. 1. Diagram of the pathways by which arachidonic acid can
be metabolized and the putative sites of inhibition of the com-
pounds used in this study.
inhibit corneal neovascularization in our model. Cy-
clooxygenase inhibitors are known to cause bowel
toxicity in rodents at high doses.28 We found that
using concentrations of indomethacin ^ 1% or con-
centrations of flurbiprofen > 2.5% caused intestinal
ulcerations or peritonitis in some of the animals. We
thus present results only for lower concentrations of
these drugs.
Quantitation of Corneal Neovascularization
The procedure for quantitating corneal neovascu-
larization has been described in detail elsewhere.27 In
Table 1. Effect of inhibitors of arachidonic acid
metabolism on corneal neovascularization
Drug % Inhibition ± 1 SEM
Corticosteroids
0.1% Dexamethasone 68.8 ± 4.4
1.0% Prednisolone 60.7 ± 2.1
Cyclooxygenase inhibitors
0.1% Flurbiprofen 24.4 ± 5.3
1.0% Flurbiprofen 33.3 ± 6.6
0.1% Indomethacin 33.7 ± 7.5
0.5% Ketorolac 23.9 ± 6.2
Lipoxygenase inhibitors
1.0% REV 5901 14.9 ± 7.7
1.0% Esculetin 4.9 ± 14.3
1.0% Quercetin -9.2 ± 4.4
Dual cyclooxygenase/lipoxygenase inhibitors
.0%BWA540C 13.5+ 3.7
.0%BW755C 8.1 ± 6.2
<0.001
<0.001
0.002
0.03
<0.002
0.007
NS
NS
NS
NS
NS
Animals were treated topically four times per day. There were eight rats in
each group and the average % corneal vascularization of the two eyes from
each animal was used for statistical analysis. The % inhibition was calculated
by comparing the % corneal vascularization of each drug treated animal to
the mean % corneal vascularization of a group of control rats which were
simultaneously treated with drug vehicle. Statistical significance was calcu-
lated by comparing each experimental group of animals to its appropriate
control group using student t-test. SEM = standard error of the mean; NS
= not statistically significant (P > 0.05).
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Fig. 2. Photomicrographs of ink-filled vessels in the corneas
of rats four days after chemical cauterization. The central black
area is the cautery site. (A) Comea of animal treated with drug
vehicle with vessels occupying 35.3% of the corneal area. (B)
Cornea of animal treated with 0.1% dexamethasone with vessels
occupying 10.3% of the corneal area. (C) Cornea of animal
treated with 1.0% flurbiprofen with vessels occupying 26.1 % of
the corneal area (X11.5).
brief, each animal was killed with a fatal dose of intra-
peritoneal sodium pentobarbital 4 days after corneal
cauterization and then perfused with lactated
Ringer's solution (to remove blood from the circula-
tion) followed by 10-20 ml of a mixture of 10% Hig-
gins Drawing Ink (Faber-Castell Corp., Newark, NJ)
mixed with 11% gelatin in lactated Ringer's solution.
Corneal flat preparations were prepared, masked to
minimize observer bias, and then analyzed by com-
puterized image analysis with a Lemont OASYS
video input image analyzer (LeMont Scientific, State
College, PA). Images of corneal flat preparations with
their ink-filled blood vessels were magnified approxi-
mately X10 and digitized for gray-scale analysis. The
area of each cornea and its blood vessels were inde-
pendently determined and the percent of the corneal
area occupied by blood vessels was computed for
each specimen.
Statistics
Percent vascularization was determined for both
corneas of each rat and the values were averaged to
compensate for positive correlation between the eyes
of each animal.29 The percent inhibition was calcu-
lated by comparing the percent corneal vasculariza-
tion of each drug treated animal to the mean percent
corneal vascularization of a group of control rats
which were simultaneously treated with drug vehicle.
Statistical significance was calculated by comparing
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Fig. 3. Dose-response curve for inhibition of corneal neovascu-
larization by dexamethasone. There were eight rats in each group
and the average % corneal vascularization of the two eyes from each
animal was used for statistical analysis. The % inhibition was cal-
culated by comparing the % corneal vascularization of each drug
treated animal to the mean % corneal vascularization of a group of
control rats which were simultaneously treated with drug vehicle.
Each error bar represents one standard error of the mean. Statisti-
cally significant (P < 0.05) inhibition of corneal neovascularization
is denoted with an *.
each experimental group of animals to its appropriate
control group using student t-test. Calculations were
performed using an IBM PC/AT computer pro-
grammed with the EPISTAT statistical package (T. L.
Gustafson, Round Rock, TX).
Results
Initially, we examined the effects of the topical ap-
plication of two corticosteroids and three cyclooxy-
genase inhibitors at concentrations that previously
had been shown to reduce the neovascular response
in various experimental models of corneal neovascu-
larization. We also evaluated three lipoxygenase in-
hibitors and two dual inhibitors at concentrations
similar to those used for the cyclooxygenase inhibi-
tors. Table 1 shows the results of these studies. The
topical application of corticosteroids markedly re-
duced corneal neovascularization following silver/
potassium nitrate cauterization (Fig. 2A, B). The
nonsteroidal cyclooxygenase inhibitors decreased
corneal neovascularization, but to a lesser degree
than corticosteroids (Fig. 2C). Neither 1.0% quercetin
nor 1.0% esculetin, two inhibitors of both 5- and 12-
lipoxygenases,30"32 significantly affected corneal neo-
vascularization. Similarly, 1.0% REV 5901, an inhib-
itor of 5-lipoxygenase, had no effect on neovascular-
ization in our model. Neither of the dual inhibitors
(1.0% BW 755C and 1.0% BW A540C) significantly
reduced the neovascular response.
The results of the dose-response experiments using
a representative compound from each class of inhibi-
tors are shown in Figures 3 and 4 and Table 2. The
corticosteroid dexamethasone was found to be supe-
o
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c
o
O
- 20-
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-20
0.01 0.10
Flurbiprofen Concentration ( % )
Fig. 4. Dose-response curve for inhibition of corneal neovascu-
larization by flurbiprofen. The calculations and symbols are the
same as those in Figure 3.
rior to the cyclooxygenase inhibitor flurbiprofen in its
ability to reduce neovascularization in this model,
while no significant inhibition was noted with either
REV 5901, a lipoxygenase inhibitor, or BW 755C, a
dual inhibitor, even at high doses.
Discussion
We have used a quantitative method to demon-
strate that topically applied corticosteroids and cy-
clooxygenase inhibitors can reduce neovasculariza-
tion in response to corneal cauterization with silver/
potassium nitrate. These results agree with previous
studies using semiquantitative methods and a variety
of corneal injuries.15"21 Our finding that corticoste-
roids are more effective than cyclooxygenase inhibi-
tors in suppressing corneal neovascularization is at
variance with several other studies that have sug-
Table 2. Effect of REV 5901 and BW 755C
on corneal neovascularization
Drug
REV 5901
REV 5901
REV 5901
REV 5901
REV 5901
BW 755C
BW 755C
BW 755C
BW 755C
BW 755C
Concentration
0.01%
0.1%
1.0%
2.5%
5.0%
0.01%
0.1%
1.0%
2.5%
5.0%
% Inhibition
± 1 SEM
12.6 ± 11.1%
-20.4 ± 6.1%
8.1 ± 6.2%
U . 8 ± 9.3%
1.7 ± 4.1%
7.5 ± 9.4%
-6.7 ± 10.9%
14.9 ± 7.7%
-6 .3 ± 7.0%
-3.8 ± 7.2%
P
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
Animals were treated topically four times per day. There were eight rats in
each group and the average % corneal vascularization of the two eyes from
each animal was used for statistical analysis. The % inhibition was calculated
by comparing the % corneal vascularization of each drug-treated animal to
the mean % corneal vascularization of a group of control rats which were
simultaneously treated with drug vehicle. Statistical significance was calcu-
lated by comparing each experimental group of animals to its appropriate
control group using student t-test. SEM = standard error of the mean; NS
= not statistically significant (P > 0.05).
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gested that cyclooxygenase inhibitors are as effective
as corticosteroids in their ability to inhibit the in-
growth of new vessels into the cornea in response to
injury.1518'2021 The discrepancies between our study
and previous studies may be explained by improved
quantitation of the neovascular response and/or dif-
ferences in drug dosage regimens, animal species and
type of injury.
We confirmed Mahoney and Waterbury's19 obser-
vation that the topical application of the dual inhibi-
tor phenidone reduces corneal neovascularization in
the rat in response to silver nitrate cautery (data not
shown). However, topical administration of pheni-
done caused an immediate and persistent blackening
of the cautery site, indicating reduction of the silver.
Phenidone is a photographic developer,33 and we su-
spect that the diminished corneal neovascularization
observed after application of phenidone reflects its
effect on the cautery site rather than the inhibitory
effect of this drug on lipoxygenases and cyclooxygen-
ase. This possibility is supported by the observation
that two structural analogues of phenidone, BW
755C and BW A540C,25 neither reduced the silver
nor altered the corneal vascularization.
The mechanism whereby corticosteroids and cy-
clooxygenase inhibitors reduce corneal neovascular-
ization in response to injury remains uncertain. How-
ever, an inhibition of arachidonic acid metabolism
and the reduced formation of inflammatory media-
tors such as prostaglandins, HETEs and leukotrienes
may play a role. If such is the case, one would also
expect dual cyclooxygenase/lipoxygenase inhibitors,
like BW 755C and BW A540C, to suppress angiogen-
esis, contrary to the current study. The inability of
BW 755C and BW A540C to suppress angiogenesis
may be due to an idiosyncratic effect of these com-
pounds that balances an inhibition of cyclooxygen-
ase. In theory, our failure to demonstrate an inhibi-
tory effect on corneal neovascularization with dual
inhibitors or with lipoxygenase inhibitors could be
due to their poor penetration into the cornea. How-
ever, Bhattacherjee et al34 reported that a solution of
BW 755C applied topically to rat corneas reduced
aqueous humor leukocyte counts and anterior uveal
vasodilatation induced by subcutaneous injection of
lipopolysaccharides, and topically applied Rev 5901
has been shown to inhibit experimentally induced
ocular inflammation in rabbits in two different
models.35-36
Our results suggest that products of the lipoxygen-
ase pathways may not be involved in the corneal neo-
vascular response in this experimental model. How-
ever, this situation may not pertain to all aspects of
corneal angiogenesis since Verbey et al35 noted that
the topical application of 1% REV 5901 decreased the
duration that blood vessels persisted in rabbit corneas
with immunogenic keratitis.
Further studies will be necessary to determine
whether the reduced corneal neovascularization fol-
lowing the topical application of corticosteroids or
cyclooxygenase inhibitors is or is not positively cor-
related with inhibited arachidonic acid metabolism.
This will be crucial since numerous components of
the inflammatory response (both cellular and hu-
moral) are potential sources of angiogenic factors,37
and corticosteroids reduce the inflammatory re-
sponse by multiple mechanisms.23'24 Similarly, cy-
clooxygenase inhibitors may counteract inflamma-
tion without altering arachidonate metabolism.38 At
the present, however, the simplest interpretation of
our data is that corneal angiogenesis is reduced by
inhibition of cyclooxygenase, as well as by other, as
yet poorly defined, steroid-dependent mechanisms.
Key words: cornea, angiogenesis, arachidonic acid, cortico-
steroids, nonsteroidal antiinflammatory agents
Acknowledgment
We thank M. Samir Jafri for assistance with perfusing the
rats.
References
1. Salmon JA and Higgs GA: Prostaglandins and leukotrienes as
inflammatory mediators. Br Med Bull 43:285, 1987.
2. Bhattacherjee P and Eakins KE: Lipoxygenase products: Me-
diation of inflammatory responses and inhibition of their for-
mation. In The Leukotrienes, Chakrin LW and Bailey DM,
editors. Orlando, Academic Press, 1984, pp. 195-215.
3. Vanderhoek JY: Biological effects of hydroxy fatty acids. In
Biochemistry of Arachidonic Acid Metabolism, Lands WEM,
editor. Boston, Martinus Nijhoff Publishing, 1985, pp.
213-226.
4. Palmblad J, Gyllenhammar H, Ringertz B, Serhan CN, Sa-
muelsson B, and Nicolaou KC: The effects of lipoxin A and
lipoxin B on functional responses of human granulocytes.
Biochem Biophys Res Commun 145:168, 1987.
5. McGiff JC and Carroll MA: Cytochrome P-450-related ara-
chidonic acid metabolites. Am Rev Resp Dis 136:488, 1987.
6. Capdevila J, Yadagiri P, Manna S, and Falck JR: Absolute
configuration of the hydroxyeicosatetraenoic acids (HETEs)
formed during catalytic oxygenation of arachidonic acid by
microsomal cytochrome P450. Biochem Biophys Res Com-
mun 141:1007, 1986.
7. Evans JF, Leblanc Y, Fitzsimmons BJ, Charleson S, Nathaniel
D, and Leveille C: Activation of leukocyte movement and
displacement of [3H]leukotriene B4 from leukocyte membrane
preparations by 12(R)- and 12(S)-hydroxyeicosatetraenoic
acid. Biochim Biophys Acta 917:406, 1987.
8. Frucht J and Zauberman H: Topical indomethacin effect on
neovascularization of the cornea and on prostaglandin E2
levels. Br J Ophthalmol 68:656, 1984.
9. Bonney RJ, Opas EE, and Humes JL: Lipoxygenase pathways
of macrophages. Fed Proc 44:2933, 1985.
10. Karmali RA: Eicosanoids in neoplasia. Prev Med 16:493,
1987.
Downloaded from iovs.arvojournals.org on 08/20/2019
No. 7 INHIBITION OF CORNEAL NEOVASCULARJZATION / Hoynes er ol 1593
11. Ben Ezra D: Neovasculogenic ability of prostaglandins, growth
factors, and synthetic chemoattractants. Am J Ophthalmol
86:455, 1978.
12. Ziche M, Jones J, and Gullino PM: Role of prostaglandin Ei
and copper in angiogenesis. J NatI Cane Inst 69:475, 1982.
13. Form DM and Auerbach R: PGE2 and angiogenesis. Proc Soc
ExpBiolMed 172:214, 1983.
14. Rochels R: Tierexperimentelle Untersuchungen zur Rolle von
Entzundungsmediatoren bei der Hornhautneovaskularisation.
Doc Ophthalmol 57:215, 1984.
15. Cooper CA, Bergamini MVW, and Leopold IH: Use of flurbi-
profen to inhibit corneal neovascularization. Arch Ophthalmol
98:1102, 1980.
16. Deutsch TA and Hughes FH: Suppressive effects of indometh-
acin on thermally induced neovascularization of rabbit cor-
neas. Am J Ophthalmol 87:536, 1979.
17. Duffin RM, Weissman OD, Glasser DB, and Pettit TH: Flur-
biprofen in the treatment of corneal neovascularization in-
duced by contact lenses. Am J Ophthalmol 93:607, 1982.
18. Harvey PT and Cherry PMH: Indomethacin vs dexametha-
sone in the suppression of corneal neovascularization. Can J
Ophthalmol 18:293, 1983.
19. Mahoney JM and Waterbury LD: Drug effects on the neovas-
cularization response to silver nitrate cauterization of the rat
cornea. Curr Eye Res 4:531, 1985.
20. Robin JB, Regis-Pacheco LF, Kash RL, and Schanzlin DJ: The
histopathology of corneal neovascularization: Inhibitor effects.
Arch Ophthalmol 103:284, 1985.
21. Parke A, Bhattacherjee P, Palmer RMJ, and Lazarus NR:
Characterization and quantification of copper sulfate-induced
vascularization of the rabbit cornea. Am J Pathol 130:173,
1988.
22. Vane J: The evolution of non-steroidal anti-inflammatory
drugs and their mechanism of action. Drugs 33(Suppl 1):18,
1987.
23. Di Rosa M, Calignano A, Carnuccio R, Ialenti A, and Sautebin
L: Multiple control of inflammation by glucocorticcids.
Agents Actions 17:284, 1985.
24. Webb DSA and Roth JA: Relationship of glucocorticoid sup-
pression of arachidonic acid metabolism to alteration of neu-
trophil function. J Leukocyte Biol 41:156, 1987.
25. Higgs GA, Flower RJ, and Vane JR: A new approach to anti-
inflammatory drugs. Biochem Pharmacol 28:1959, 1979.
26. Marsh RJ and Maurice DM: The influence of non-ionic deter-
gents and other surfactants on human corneal permeability.
ExpEyeRes 11:43, 1971.
27. Proia AD, Chandler DB, Haynes WL, Smith CF, Suvarnamani
C, Erkel FH, and KJintworth GK: Quantitation of corneal
neovascularization using computerized image analysis. Lab
Invest 58:473, 1988.
28. Brodie DA, Cook PG, Bauer BJ, and Dagle GE: Indometha-
cin-induced intestinal lesions in the rat. Toxicol Appl Phar-
macol 17:615, 1970.
29. Ray WA and O'Day DM: Statistical analysis of multi-eye data
in ophthalmic research. Invest Ophthalmol Vis Sci 26:1186,
1985.
30. Hope WC, Welton AF, Fiedler-Nagy C, Batula-Bernardo C,
and Coffey JW: In vitro inhibition of the biosynthesis of slow
reacting substance of anaphylaxis (SRS-A) and lipoxygenase
activity by quercetin. Biochem Pharmacol 32:367, 1983.
31. Neichi T, Koshihara Y, and Murota S: Inhibitory effect of
esculetin on 5-lipoxygenase and leukotriene biosynthesis. Bio-
chim Biophys Acta 753:130, 1983.
32. Sekiya K, Okuda H, and Arachi S: Selective inhibition of plate-
let lipoxygenase by esculetin. Biochim Biophys Acta 713:68,
1982.
33. Blackwell GJ and Flower RJ: l-phenyl-3-pyrazolidone: An in-
hibitor of cyclo-oxygenase and lipoxygenase pathways in lung
and platelets. Prostaglandins 16:417, 1978.
34. Bhattacherjee P, Williams RN, and Eakins ICE: A comparison
of the ocular anti-inflammatory activity of steroidal and non-
steroidal compounds in the rat. Invest Ophthalmol Vis Sci
24:1143, 1983.
35. Verbey NLJ, van Haeringen NJ, and de Jong PTVM: Modula-
tion of immunogenic keratitis in rabbits by topical administra-
tion of inhibitors of lipoxygenase and cyclooxygenase. Curr
Eye Res 7:361, 1988.
36. Chiou LY and Chiou GCY: Ocular anti-inflammatory action
of a lipoxygenase inhibitor in the rabbit. J Ocular Pharmacol
1:383, 1985.
37. KJintworth GK: Corneal neovascularization: An overview. In
Ocular Circulation and Neovascularization, Ben Ezra D, Ryan
SJ, Glaser BM, and Murphy RP, editors. Dordrecht, Martinus
Nijhoff/Dr. W. Junk Publishers, 1987, pp. 327-333.
38. Weissmann G: Pathogenesis of inflammation—effects of the
pharmacological manipulation of arachidonic acid metabo-
lism on the cytological response to inflammatory stimuli.
Drugs 33(Suppl 1):28, 1987.
Downloaded from iovs.arvojournals.org on 08/20/2019
